These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21449707)

  • 1. Synthesis and in vivo bioactivity of lipophilic alendronate derivatives against osteoporosis.
    Lu TL; Hu HJ; Zhao W; Chen T
    Drug Dev Ind Pharm; 2011 Jun; 37(6):656-63. PubMed ID: 21449707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis.
    Vachal P; Hale JJ; Lu Z; Streckfuss EC; Mills SG; MacCoss M; Yin DH; Algayer K; Manser K; Kesisoglou F; Ghosh S; Alani LL
    J Med Chem; 2006 Jun; 49(11):3060-3. PubMed ID: 16722624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.
    Arns S; Gibe R; Moreau A; Monzur Morshed M; Young RN
    Bioorg Med Chem; 2012 Mar; 20(6):2131-40. PubMed ID: 22341574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
    Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ
    Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ovariectomy and alendronate on implant osseointegration in rat maxillary bone.
    Viera-Negrón YE; Ruan WH; Winger JN; Hou X; Sharawy MM; Borke JL
    J Oral Implantol; 2008; 34(2):76-82. PubMed ID: 18478902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
    Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
    J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.
    Armamento-Villareal R; Napoli N; Panwar V; Novack D
    N Engl J Med; 2006 Nov; 355(19):2048-50. PubMed ID: 17093260
    [No Abstract]   [Full Text] [Related]  

  • 8. Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.
    Xie H; Chen G; Young RN
    J Med Chem; 2017 Aug; 60(16):7012-7028. PubMed ID: 28699744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.
    Losada BR; Zanchetta JR; Zerbini C; Molina JF; De la Peña P; Liu CC; Smith RB; Nino AJ; Krohn K; Warner MR
    J Clin Densitom; 2009; 12(1):63-70. PubMed ID: 19028124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate.
    Derakhshanian H; Djalali M; Djazayery A; Nourijelyani K; Ghadbeigi S; Pishva H; Saedisomeolia A; Bahremand A; Dehpour AR
    Can J Physiol Pharmacol; 2013 May; 91(5):380-5. PubMed ID: 23656499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
    Kusamori K; Katsumi H; Abe M; Ueda A; Sakai R; Hayashi R; Hirai Y; Quan YS; Kamiyama F; Sakane T; Yamamoto A
    J Bone Miner Res; 2010 Dec; 25(12):2582-91. PubMed ID: 20533374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of alendronate on the healing of extraction sockets of ovariectomized rats assessed by in vivo micro-computed tomography.
    Jee JH; Lee W; Lee BD
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Aug; 110(2):e47-53. PubMed ID: 20591699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats.
    Srisubut S; Teerakapong A; Vattraphodes T; Taweechaisupapong S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Oct; 104(4):e11-6. PubMed ID: 17656137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sol-gel derived titania coating with immobilized bisphosphonate enhances screw fixation in rat tibia.
    Linderbäck P; Areva S; Aspenberg P; Tengvall P
    J Biomed Mater Res A; 2010 Aug; 94(2):389-95. PubMed ID: 20186735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
    Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
    J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats.
    Sun P; Cai DH; Li QN; Chen H; Deng WM; He L; Yang L
    Calcif Tissue Int; 2010 Jun; 86(6):495-501. PubMed ID: 20390406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.
    Follet H; Li J; Phipps RJ; Hui S; Condon K; Burr DB
    Bone; 2007 Apr; 40(4):1172-7. PubMed ID: 17240209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of distortion of vascular deprivation-induced osteonecrosis of the rat femoral head by treatment with alendronate.
    Peled E; Bejar J; Zinman C; Boss JH; Reis DN; Norman D
    Arch Orthop Trauma Surg; 2009 Feb; 129(2):275-9. PubMed ID: 18523789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
    Feher A; Koivunemi A; Koivunemi M; Fuchs RK; Burr DB; Phipps RJ; Reinwald S; Allen MR
    Bone; 2010 Jan; 46(1):203-7. PubMed ID: 19857619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.